Real-time multi-spectral imaging for accurate detection of cancerous tissue in endoscopic surgery

Cancer is the leading cause of death in the EU, with 2.7M diagnoses and 1.3M deaths in 2020.

Effective removal of cancerous tissue through endoscopic surgery is challenging because of limited visual and absent tactile information, along the limitations of current imaging technologies, which make it difficult for surgeons to differentiate between different types of tissue.

For this market, Thericon is developing an rMSI (real-time multispectral imaging) platform providing surgeons with multi-parametric images that help with effective removal of cancerous tissue and reduction of cancer recurrence in patients.

The company has developed a prototype for its first product, named rMSI 2, and completed initial validation for bladder cancer applications.

Thericon is asking for a 2.5M EIC grant and 5.5M equity funding to complete clinical application pilots, safety tests and CE certification for this product, getting it ready for market launch in 2024.